Calyxt has filed a registration statement with the US Securities and Exchange Commission (SEC) as part of the previously announced merger with Cibus (see AgbioNews Jan 17, 2023). The combined company is expected to be renamed Cibus Inc. and will remain listed on the Nasdaq Capital Market under CBUS. The transaction remains expected to close in the second quarter of 2023, subject to customary closing conditions.